Shares of Repro Med (OOTC:REPR) are little changed following the company’s 2016 second quarter results. We view this as an encouraging sign that the market may finally be ready to shrug off the lingering issue of the FDA Warning letter that […]
Shares of Repro Med (OOTC:REPR) are little changed following the company’s 2016 second quarter results. We view this as an encouraging sign that the market may finally be ready to shrug off the lingering issue of the FDA Warning letter that […]